Taysha Gene Therapies, Inc. TSHA EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Taysha Gene Therapies, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s EBITDA margin?
- Taysha Gene Therapies, Inc. (TSHA) reported EBITDA margin of -1,759.7% in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s EBITDA margin changed year-over-year?
- Taysha Gene Therapies, Inc.'s EBITDA margin decreased by 45.5% year-over-year, from -1,209.3% to -1,759.7%.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s EBITDA margin?
- Over 3 years (2022 to 2025), Taysha Gene Therapies, Inc.'s EBITDA margin has grown at a -44.2% compound annual growth rate (CAGR), from -6,443.8% to -1,119.6%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.